...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Question for the board!
1
Jan 22, 2019 11:11AM
2
Jan 22, 2019 12:13PM

acccchhh,,,,,the costing is not that prohibitive,,,,,,,,,,,,;

    TSX Venture Exchange
Listing Fees   $7,500 - $40,000
Accounting and Auditing Fees   $25,000 - $100,000
Legal Fees   $75,000+
Underwriters' Commission   Up to 12 %

------------------------------------------------------------------

                                          $ 150,000   Mid range costing.

2
Jan 22, 2019 12:46PM
5
Jan 22, 2019 01:39PM
4
Jan 22, 2019 01:40PM
3
Jan 22, 2019 02:24PM
6
Jan 22, 2019 04:23PM
5
Jan 22, 2019 04:53PM
3
Jan 22, 2019 05:56PM
Share
New Message
Please login to post a reply